Similar Items: Mining the FAERS database reveals new safety signals for 120 mg denosumab in oncology practice
- Assessing the real-world safety of vutrisiran for transthyretin-mediated amyloidosis with polyneuropathy: Based on WHO-VigiAccess and FAERS databases
- Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy using spontaneous reports: A 20-year signal detection study based on the FAERS database
- Comprehensive post-marketing safety evaluation of atezolizumab: A disproportionality analysis based on individual case safety reports in the FAERS
- Expression-driven genetic dependency reveals targets for precision oncology
- Real-world safety of aliskiren in primary hypertension: A cross-database study
- Correction: Endocrine advantages of PD-1/PD-L1 therapy: Comparative analysis of FAERS-JADER